Sign In
Buy ABT
$90.51
-0.0200 (-0.0221%)
At Close: Jun 24, 2026
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
10:47am, Wednesday, 22'nd Jan 2025
Abbott Laboratories (NYSE:ABT ) Q4 2024 Earnings Conference Call January 22, 2025 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman & Chief Execu
Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics
10:31am, Wednesday, 22'nd Jan 2025
The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
10:17am, Wednesday, 22'nd Jan 2025
On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
Abbott (ABT) Q4 Earnings Meet Estimates
09:16am, Wednesday, 22'nd Jan 2025
Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago.
Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates
08:39am, Wednesday, 22'nd Jan 2025
Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.
Abbott forecasts in line annual profit on medical device sales
07:02am, Wednesday, 22'nd Jan 2025
Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitor
Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
07:00am, Wednesday, 22'nd Jan 2025
Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 p
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
06:00am, Tuesday, 21'st Jan 2025
When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- that might follow. A particular stock will rise or fall, and we'll benefit o
HAE or ABT: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 20'th Jan 2025
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued sto
Abbott Stock Ahead of Q4 Earnings Results: Smart Buy or Risky Move?
12:11pm, Monday, 20'th Jan 2025
Abbott's Diagnostics arm is expected to have been driven by the widespread adoption of its top-tier systems and high testing demand in the fourth quarter.
Unlocking Q4 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
10:20am, Thursday, 16'th Jan 2025
Evaluate the expected performance of Abbott (ABT) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics f
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
07:30am, Thursday, 16'th Jan 2025
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 15'th Jan 2025
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?
11:40am, Wednesday, 08'th Jan 2025
ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.
Abbott Laboratories Q4 2024 Earnings Preview
08:30am, Wednesday, 08'th Jan 2025
Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. Abbott continues to execute growth businesses with excellent marketing and distributio
